Olaparib (AZD2281, Ku-0059436)

製品コードS1060

Olaparib (AZD2281, Ku-0059436)化学構造

分子量(MW):434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 24900.00
JPY 61420.00

文献中Selleckの製品使用例(89)

カスタマーフィードバック(18)

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明 Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
特性 A potent PARP inhibitor (currently in late stage clinical trials).
ターゲット
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
体外試験

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPlWmxxPCCm NHnQdlZKSzVyPUWuO|A2KCEQvF2g M2S3S|E5PTV7NkGz
KP6.3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[0JIQ> NXrQW5Z3UUN3ME2xNE41OjhizszNJC=> M1rXUVE5PTV7NkGz
KP7.7 M{i1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f4b|Qh\A>? M1HOV2lEPTB;NUegcm0h NWLNeJB[OTh3NUm2NVM>
KB2P3.4 NY[0dI9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPuOEBl MWTJR|UxRTF{NDDNJC=> MoLKNVg2PTl4MUO=
KB2P1.21 NYnJbW94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPXd3Y1KGR? MlnrTWM2OD16OUC3JI5OKA>? M37u[FE5PTV7NkGz
U373-MG NIm0cY5EgXSxdH;4bYMhSXO|YYm= M1[0R|Eh|ryPIB?= MX[yOEBp MkPOTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NYXTZm84OTh7NUS3NVI>
T98G NHu4VmdEgXSxdH;4bYMhSXO|YYm= M2TUV|Eh|ryPIB?= NW\xZmRDOjRiaB?= M1G4S2lv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NYjQSHBQOTh7NUS3NVI>
U87-MG M1;JUGN6fG:2b4jpZ{BCe3OjeR?= NXLtNG9mOSEQvF2g MWGyOEBp NEDmUZlKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NXfkVoI{OTh7NUS3NVI>
UVW M2fwZWN6fG:2b4jpZ{BCe3OjeR?= NWL6WXVZPTByIH7N MUmyOEBp M3fndWlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? MlLCNVg6PTR5MUK=
HeLa MVnGeY5kfGmxbjDBd5NigQ>? NGTLd4Y2ODBibl2= NFzEbGs1KGh? NV[xeIx7S2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| NVT0XFN{OTh7NUS3NVI>
HeLa MVfGeY5kfGmxbjDBd5NigQ>? NEXy[JgyKM7:TTC= MYqyOEBp MVzFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? MnzFNVg6PTR5MUK=
T98G NGfYXJdHfW6ldHnvckBCe3OjeR?= M1LEPVEh|ryPIB?= MmTjNlQhcA>? Ml20SY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? MmrvNVg6PTR5MUK=
L3 NInGfYxEgXSxdH;4bYMhSXO|YYm= MYC1JO69VSB? NEThdXg6PiCq MXLEUXNQ NF[5OVhUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> MVuyNFEzPDR3OR?=
Granta-519 NXXxUJNyS3m2b4TvfIlkKEG|c3H5 MlzPOUDPxE1i MWW5OkBp M3;hTmROW09? NXjtSmo2W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MW[yNFEzPDR3OR?=
BT M4PPdmN6fG:2b4jpZ{BCe3OjeR?= MX[1JO69VSB? MVO5OkBp M3XvNWROW09? MX7TcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NVPnSHBGOjBzMkS0OVk>
UPN2 NUTHfXloS3m2b4TvfIlkKEG|c3H5 NGLRUWs2KM7:TTC= Mn;0PVYhcA>? M1iwfmROW09? MYXTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NUfTU|lsOjBzMkS0OVk>
HBL-2 NXvTWJVJS3m2b4TvfIlkKEG|c3H5 NIXadWg2KM7:TTC= MlnjPVYhcA>? Mn7XSG1UVw>? NWr3Z21qW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= Ml;TNlAyOjR2NUm=
JVM-2 NYTCNoFLS3m2b4TvfIlkKEG|c3H5 MXy1JO69VSB? MVu5OkBp MYHEUXNQ M2LBe3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? M1;1SlIxOTJ2NEW5
Z138 MnH2R5l1d3SxeHnjJGF{e2G7 MWO1JO69VSB? NHfCeos6PiCq NXHpcGdWTE2VTx?= NVzEXHRWW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MWOyNFEzPDR3OR?=
RWPE MW\JcpZie2m4ZTDBd5NigQ>? NGDXclczPSEQvF2= NH;jdZQ1QCCq NVrWO5d{TE2VTx?= M4TKXXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> NGrvdHUzOTV5NUi2OS=>
VCaP MVLJcpZie2m4ZTDBd5NigQ>? MoHtNlUh|ryP MWm0PEBp NVHBTYFQTE2VTx?= M{\rSXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> MnzsNlE2PzV6NkW=
Mouse H2AX−/− ES Cells NHfQfmhEgXSxdH;4bYMhSXO|YYm= M1H6cFIvPSEQvF2= NEXXbHMzOCCq MmDvV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NG\6N5MzOzN3NUS4PS=>
Mouse ATM−/− ES Cells NXLVPZBIS3m2b4TvfIlkKEG|c3H5 M{nlbFIvPSEQvF2= M2LWVFIxKGh? MVfTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= MXKyN|M2PTR6OR?=
H1650 NV7mRolDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVqyNEDPxE1? MmPRNVQ1KGh? NE\iVJBKSzVyPUG1MlQ4KM7:TR?= NVu5[mlWOjN{M{m4NFk>
H1650PTEN+ M{DpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[yNEDPxE1? MlXGNVQ1KGh? NX7vdmloUUN3ME21NE45OyEQvF2= NYfSXZhvOjN{M{m4NFk>
PC-9 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIixWlkzOCEQvF2= MWqxOFQhcA>? NHrYUWxKSzVyPUWuPFgh|ryP NVToUoNCOjN{M{m4NFk>
PC-9PTEN− MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLTNlAh|ryP NX;Eb4pHOTR2IHi= NHnUdpRKSzVyPU[uOVIh|ryP NVvkfFVJOjN{M{m4NFk>
MDA-MB-231 M{LKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmflOUBl[Xl? MlzhTWM2OD14Lkmg{txO MXKyN|c3ODR7Nh?=
MDA-MB-468 NFLhN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfSbm1HPSCmYYm= NYHHV5QzUUN3ME21MlAh|ryP NF3XUWkzOzd4MES5Oi=>
BT20 NXm0WZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfvOUBl[Xl? M1K5N2lEPTB;Nz63JO69VQ>? MmTxNlM4PjB2OU[=
HCC1143 NIOyZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG1JIRigQ>? MXvJR|UxRTFzLkGg{txO M1myclI{PzZyNEm2
HCC1937 NY\yboxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojwOUBl[Xl? MmLNTWM2OD1zMj62JO69VQ>? MmXCNlM4PjB2OU[=
Hs578t NG\acJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe1JIRigQ>? NF\4N4pKSzVyPUWuOkDPxE1? M2jDRlI{PzZyNEm2
Hs578t(si) NFnYPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfHcHk2KGSjeR?= NX7XbnpyUUN3ME23MlUh|ryP M3PlU|I{PzZyNEm2
BT474 NIDuVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[1JIRigQ>? NE\xWW5KSzVyPUG5Mlgh|ryP MoWxNlM4PjB2OU[=
JIMT1 NYDobWpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\iUo1pPSCmYYm= NH;ib4tKSzVyPUeuO{DPxE1? M3T6UFI{PzZyNEm2
SKBR3 NGrGb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK1JIRigQ>? M2rwbWlEPTB;MUGuNUDPxE1? MnHNNlM4PjB2OU[=
SUM159 NHPZU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\OTlUh\GG7 NIroeo1KSzVyPUSuNkDPxE1? MV[yN|c3ODR7Nh?=
CAMA1 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fNZlUh\GG7 MVPJR|UxRTF3Lkig{txO MXGyN|c3ODR7Nh?=
MCF7 M3vHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXXVZJ{PSCmYYm= NUP1c|BJUUN3ME21Mlgh|ryP MXOyN|c3ODR7Nh?=
T47D Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPpUJV4PSCmYYm= M{LWemlEPTB;OT62JO69VQ>? MWqyN|c3ODR7Nh?=
HCT116 Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXyO2Z{OTByIN88US=> NYn5XJFoPDhiaB?= M{nrO2ROW09? NWn0c4E4UUN3ME2yMlUh|ryPIB?= NITrZWczPDV5N{m0NS=>
SW1116 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTp[okyODBizszN M1HOR|Q5KGh? M4\1ZWROW09? NXfoeY83UUN3ME2xNFAh|ryP NWSwcYFOOjR3N{e5OFE>
HT29 M2r5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\PdlExOCEQvF2= MnvvOFghcA>? M{TEVmROW09? M3HOOmlEPTB;MUSuO{DPxE1? MmnJNlQ2Pzd7NEG=
LoVo M133Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzmU4xTOTByIN88US=> NHH4bIQ1QCCq NETZWVJFVVOR MnHUTWM2OD1zMz60JO69VQ>? M1XySlI1PTd5OUSx
HCT-15 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNFAh|ryP NGjNeYU1QCCq NXLPVoNGTE2VTx?= MnvuTWM2OD1zMDFOwG0> NEHJNYQzPDV5N{m0NS=>
SW48 NViwRoNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHwfmEyODBizszN NGPOZVc1QCCq NYW2NItSTE2VTx?= M1LuSGlEPTB;OT61JO69VQ>? MmrHNlQ2Pzd7NEG=
C-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xNFAh|ryP MYS0PEBp M1fVT2ROW09? MoDlTWM2OD15Lk[g{txO MlvuNlQ2Pzd7NEG=
RKO NEP0d3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxNFAh|ryP MVe0PEBp MkCzSG1UVw>? NGD0cZNKSzVyPUWuPUDPxE1? NUP2WpRyOjR3N{e5OFE>
HCT116 M3zSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNFAh|ryP MWS0PEBp NXH4b41wTE2VTx?= MnWwVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MWGyOFU4Pzl2MR?=
SW1116 NIrqemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlezNVAxKM7:TR?= MWi0PEBp M2Xj[WROW09? NEDYN5NRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NFPEb4YzPDV5N{m0NS=>
HT29 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLxZZB[OTByIN88US=> M3;SNVQ5KGh? MVPEUXNQ MWrQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh M1nrflI1PTd5OUSx
LoVo NFrxN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fFWlExOCEQvF2= MWO0PEBp MXXEUXNQ M2\TfnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? M2rhSlI1PTd5OUSx
SW48 M3\ab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGxNFAh|ryP M1n2bFQ5KGh? M4C3cGROW09? NILHVWZRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NUSze5ltOjR3N{e5OFE>
C-1 M{XqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf1XVMyODBizszN NYXwfItXPDhiaB?= MVXEUXNQ M1\aU3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NY\FRlJsOjR3N{e5OFE>
RKO MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i0fFExOCEQvF2= MWm0PEBp NVvDXW5DTE2VTx?= M1\HfHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? M{XnVFI1PTd5OUSx
HCT116 M{DOW2Z2dmO2aX;uJGF{e2G7 NXnPNY5[OTBibl2= M1TZclEzKGh? MXXEUXNQ MlqxTY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 MX2yOFU4Pzl2MR?=
HT29 NWL3TWpjTnWwY4Tpc44hSXO|YYm= MXGxNEBvVQ>? MV6xNkBp Ml7ISG1UVw>? Mnr3TY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 M12wOlI1PTd5OUSx
TE-6 MXHGeY5kfGmxbjDBd5NigQ>? MlfBOUDPxE1i M17MSlEzKGh? M{C3NWROW09? NFzYPI5KdmS3Y3XzJGczN01iYYLy[ZN1 MnTnNlQzOTlzNkS=
TE-6 NHjwPIVHfW6ldHnvckBCe3OjeR?= NELqNW82KM7:TTC= MUGyOEBp M2\RTGROW09? NVLmO3l5UW6lcnXhd4V{KGmwIHTveYJt\SC|dILhcoQh[nKnYXvzJEhFW0K|KR?= M1zubFI1OjF7MU[0
Hep3B NELFXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmyOFAh|ryPIB?= MknPO|IhcA>? MVXEUXNQ MV7TfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=> NFOzfowzPTB5Mke1Ni=>
Huh7 M13Sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7kdHBzPDBizszNJC=> NV\md3FHPzJiaB?= NHPS[4tFVVOR NWqweIpMW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? Ml\TNlUxPzJ5NUK=
Hep3B NE[4Z4ZHfW6ldHnvckBCe3OjeR?= NFXmbpI1OCEQvF2g NUXlNHdJOjRiaB?= M{nBXmROW09? MV7JcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? M2f2fVI2ODd{N{Wy
Huh7 NWGydppiTnWwY4Tpc44hSXO|YYm= MUW0NEDPxE1i NXWyfmt7OjRiaB?= M4nyU2ROW09? NWKyS5JYUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR NX7pOm17OjVyN{K3OVI>
Hep3B M{\jPWZ2dmO2aX;uJGF{e2G7 MnrWOFAh|ryPIB?= NE[1[2MzPCCq MXXEUXNQ Ml;FTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT MWSyOVA4Ojd3Mh?=
Huh7 MoTTSpVv[3Srb36gRZN{[Xl? NV:4[4VCPDBizszNJC=> M1zEUVI1KGh? NVnJToM1TE2VTx?= NWPBOpJxUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR MVeyOVA4Ojd3Mh?=
SGC-7901 M3PyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfPfHJlOzEEoN88US=> MV[0PEBp NIfvcIxFVVOR NVnmb24ySmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MljrNlU4PjdyN{[=
COLO-800 M2L1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwNESxOlQh|ryP MV;TRW5ITVJ?
EoL-1- NXrENYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO2bnY4UUN3ME2wMlU3PDR4IN88US=> NGjzXFdUSU6JRWK=
NCI-H209 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO5TWM2OD1yLkmxOVU3KM7:TR?= MXzTRW5ITVJ?
ES1 M3PSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLLUYlKSzVyPUGuNVE1ODhizszN NX7LTJFHW0GQR1XS
NKM-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\MTWM2OD1zLkK1N|Q4KM7:TR?= M2\FN3NCVkeHUh?=
NTERA-S-cl-D1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXBTWM2OD1zLkOzN|QyKM7:TR?= NETpXppUSU6JRWK=
MHH-ES-1 NH7rfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwNkKwOlch|ryP MYPTRW5ITVJ?
ES8 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXOXVhKSzVyPUGuO|I1OTRizszN NGDqSmdUSU6JRWK=
NCI-H720 M3H0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlruTWM2OD1{LkKwOlk6KM7:TR?= MXLTRW5ITVJ?
EW-3 NIXlXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjNZmpKSzVyPUKuNlc2OzRizszN M2XtWXNCVkeHUh?=
D-566MG NITTZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y3XmlEPTB;Mj60OFU3QCEQvF2= Mlv5V2FPT0WU
697 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHLPVJKSzVyPUKuPFQyPzNizszN Ml\uV2FPT0WU
ES5 NH\6cYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOySGRKSzVyPUKuPFgyQDlizszN MYjTRW5ITVJ?
COLO-684 NInoeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3FTWM2OD1|LkWxOlk3KM7:TR?= M2\CVXNCVkeHUh?=
ML-2 NUXXWGpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTPTWM2OD1|Lk[wNFU5KM7:TR?= NWi2fJlnW0GQR1XS
MC-IXC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SyR2lEPTB;Mz62N|M6OyEQvF2= NULRNJY2W0GQR1XS
DB NVHSR3ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvnTWM2OD1|Lk[1OFQ5KM7:TR?= Mny0V2FPT0WU
HCC2218 NInC[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTNwN{OxNFMh|ryP MXjTRW5ITVJ?
NCI-H510A NWPkXpZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfaUHFTUUN3ME2zMlgzPzJ2IN88US=> NVzld|dGW0GQR1XS
NCI-H526 NGPtUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEexR4JKSzVyPUOuPFY6PThizszN M4HuS3NCVkeHUh?=
MV-4-11 M1fuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTRwMUOzN|Qh|ryP NHnHO|BUSU6JRWK=
PA-1 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDUdVNKSzVyPUSuNlUzQSEQvF2= MoK2V2FPT0WU
EW-22 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf0XXFKSzVyPUSuN|U5PiEQvF2= MWTTRW5ITVJ?
KASUMI-1 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm1UIVKSzVyPUSuOFAyODlizszN NVXZXFV1W0GQR1XS
LU-139 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP1O|M5UUN3ME20Mlc2QDJ7IN88US=> M3zqRnNCVkeHUh?=
SBC-1 NF;XRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\DTWM2OD12LkiwPVA5KM7:TR?= M4LwWXNCVkeHUh?=
H4 NWTldG45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvqTWM2OD12Lki5OFQ{KM7:TR?= MmDoV2FPT0WU
EW-11 NULX[3dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGexZYpKSzVyPUWuNFgxPzJizszN NWDW[VVbW0GQR1XS
NBsusSR M{e0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTUV3lNUUN3ME21MlEzODV3IN88US=> NWLNN2l[W0GQR1XS
RPMI-8226 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M376SGlEPTB;NT6xOVI1PCEQvF2= NX7CWWNYW0GQR1XS
DEL M3TKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHrdJE3UUN3ME21MlIxODB4IN88US=> Moe4V2FPT0WU
ES4 NILF[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y2R2lEPTB;NT61NVM5QSEQvF2= MmOzV2FPT0WU
GCT MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTOc|NKSzVyPUWuOVY5PTZizszN M{TLZXNCVkeHUh?=
NCI-H1048 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r0fGlEPTB;NT65O|I4OyEQvF2= NHX3OXFUSU6JRWK=
NCI-SNU-1 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZwMEKyJO69VQ>? NW[5NZA{W0GQR1XS
ES7 NGry[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rWN2lEPTB;Nj6wN|U4PyEQvF2= M3;UU3NCVkeHUh?=
SW982 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkezTWM2OD14LkC5NVM4KM7:TR?= NX\YWpV2W0GQR1XS
L-363 M1;ROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfCbmxKSzVyPU[uN|M6PzRizszN Mne3V2FPT0WU
HT-1080 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHzTWM2OD14LkS5Olg{KM7:TR?= NEjER3JUSU6JRWK=
HAL-01 M1:3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe2V5dKSzVyPU[uOVExQSEQvF2= M1HzbnNCVkeHUh?=
NB14 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTZwNkSwN|kh|ryP MUXTRW5ITVJ?
EW-13 NGfUWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf6WmwyUUN3ME22Mlc4PDJ2IN88US=> MoL2V2FPT0WU
NY M4TXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHZU3hGUUN3ME22Mlk1PjB3IN88US=> NIDseZNUSU6JRWK=
NCI-SNU-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP0VpZkUUN3ME23MlExPDN|IN88US=> M2jtT3NCVkeHUh?=
MS-1 NIWwbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTdwMUe0PVQh|ryP NIG4PZVUSU6JRWK=
EW-16 M3LEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTdwM{G4OlEh|ryP MVHTRW5ITVJ?
LU-65 NUTnXohuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdwNEi0NVch|ryP Mn\kV2FPT0WU
HGC-27 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\STphKSzVyPUeuO|IyPzNizszN NEnkNoJUSU6JRWK=
CTB-1 NITVUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTdwN{[xO|Uh|ryP M2jxfHNCVkeHUh?=
5637 NHf5fZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTdwOUK4OkDPxE1? NVTzflR1W0GQR1XS
U251 M4S2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO5TWM2OD15Lkm0NFE3KM7:TR?= MVLTRW5ITVJ?
HOS M{TJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLSc|JKSzVyPUiuNlMxODdizszN NWfTNm9JW0GQR1XS
DOHH-2 M4fQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LtOWlEPTB;OD6yN|U5KM7:TR?= Ml;GV2FPT0WU
EW-1 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nLemlEPTB;OD6zNFA5QCEQvF2= MmXwV2FPT0WU
BV-173 NGmydohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS5NZJ1UUN3ME24MlU2PTRizszN M3LLdXNCVkeHUh?=
8-MG-BA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[1dmlEPTB;OD62PFk5QCEQvF2= MVHTRW5ITVJ?
NB69 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljBTWM2OD16LkewPVIyKM7:TR?= NY\ZS2VoW0GQR1XS
NCI-H69 M17uXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTlwOUC5OlEh|ryP NYjTS2VZW0GQR1XS
RS4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vJXGlEPTB;MUGuNlIxQCEQvF2= MY\TRW5ITVJ?
ONS-76 NG\0TZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFzLkK5OFch|ryP NUm3O|JDW0GQR1XS
SF539 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEewOGhKSzVyPUGxMlQ5QDlizszN NFnTRZVUSU6JRWK=
HuO-3N1 Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL1TWM2OD1zMT61O|k3KM7:TR?= NVXwXmpsW0GQR1XS
NCI-H1651 M2\B[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:0W5ZrUUN3ME2xNk4{OTF3IN88US=> NF62T2dUSU6JRWK=
KARPAS-45 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHHOndKSzVyPUGyMlM4PiEQvF2= MUHTRW5ITVJ?
SK-NEP-1 M3zFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m4c2lEPTB;MUKuOFYxQSEQvF2= NWnzVpUyW0GQR1XS
LAMA-84 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF|LkGwPVUh|ryP NFjZZYZUSU6JRWK=
NCI-H1155 M1y2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTRTWM2OD1zMz6yPFU3KM7:TR?= MVvTRW5ITVJ?
CTV-1 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL2TWM2OD1zMz60OFUh|ryP NEPybWdUSU6JRWK=
QIMR-WIL MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF|Lke4NVQh|ryP NFrOXHlUSU6JRWK=
H9 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfHNoZUUUN3ME2xN{45PDd3IN88US=> NGG2dodUSU6JRWK=
SK-MEL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3neWZnUUN3ME2xN{46OzR5IN88US=> NHHFU21USU6JRWK=
HD-MY-Z M3vMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr1bFhiUUN3ME2xOE4xPjN5IN88US=> MUTTRW5ITVJ?
TI-73 M3fDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Dlc2lEPTB;MUSuNlM2PiEQvF2= NXXFeo1jW0GQR1XS
JVM-3 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnKNnhKSzVyPUG1MlU4OTZizszN NHf0PXRUSU6JRWK=
D-247MG NILsVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nhfmlEPTB;MUWuOVk{KM7:TR?= NWHDNoFoW0GQR1XS
VA-ES-BJ M{Labmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHUTWM2OD1zNT62NFk4KM7:TR?= M2m5T3NCVkeHUh?=
NOS-1 M2XrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLVRmJNUUN3ME2xOU43PTJ{IN88US=> M2OzOXNCVkeHUh?=
MOLT-4 NVLKOGhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;YVGlEPTB;MU[uO|UzKM7:TR?= M1qyfnNCVkeHUh?=
Mo-T MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF5LkC4OFkh|ryP M3vyfXNCVkeHUh?=
NCI-H1770 M2T0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELQfIxKSzVyPUG3MlE2PDNizszN MkHXV2FPT0WU
COLO-320-HSR M3jQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF5LkG4Nlch|ryP NHPiTlVUSU6JRWK=
TE-12 NUjQRW81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\RbJZKUUN3ME2xO{44ODV2IN88US=> NV\PW5JoW0GQR1XS
NCI-H82 NUXuOJE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF5Lki3Nlgh|ryP M3;NT3NCVkeHUh?=
NEC8 M3XDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\icWlEPTB;MUiuNVMyPiEQvF2= NIrBNlhUSU6JRWK=
HSC-3 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHXeW9KSzVyPUG4Mlc1OTRizszN NEXHRm5USU6JRWK=
NCI-H1092 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ewemlEPTB;MUiuO|U6PSEQvF2= MXjTRW5ITVJ?
NCI-H292 NXzkSWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXFfIJQUUN3ME2xPU4xPDh7IN88US=> M2HVfHNCVkeHUh?=
L-428 NHzKbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3MTWM2OD1zOT61OVkh|ryP NG[5WXVUSU6JRWK=
LU-134-A NGGzbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF7LkW3NkDPxE1? MkPrV2FPT0WU
GI-ME-N M2ryPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHGWIN4UUN3ME2xPU42PzR5IN88US=> M1XqRnNCVkeHUh?=
ALL-PO NUXGbXB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrTTWM2OD1zOT61PVczKM7:TR?= MmPlV2FPT0WU
D-283MED NGflOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjXbIFKSzVyPUG5MlkyPSEQvF2= Mon0V2FPT0WU
D-423MG M{\KPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF7Lkm5Olch|ryP NVnvbJNYW0GQR1XS
CAKI-1 NVjVXGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrtTWM2OD1{MD6yNlE6KM7:TR?= MkXhV2FPT0WU
ETK-1 M2HsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnLTGdKSzVyPUKwMlI3OTVizszN MkP0V2FPT0WU
G-402 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInIVmxKSzVyPUKwMlU{OzRizszN NE\5bohUSU6JRWK=
HL-60 M{fVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xzb2lEPTB;MkGuNVYyOyEQvF2= Mo\nV2FPT0WU
A2058 NUHLeGFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLzTWM2OD1{MT60OFc4KM7:TR?= NHr4T3VUSU6JRWK=
CHP-212 NUT1Z|VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC4TWM2OD1{MT65NFUyKM7:TR?= NYe2blVGW0GQR1XS
KY821 MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2juS2lEPTB;MkGuPVc2KM7:TR?= NEjYeoFUSU6JRWK=
TYK-nu MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Wwe2lEPTB;MkKuNFY2OSEQvF2= MU\TRW5ITVJ?
JVM-2 NV[w[Wt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq3TWM2OD1{Mj6yPVg{KM7:TR?= MXXTRW5ITVJ?
KU812 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLHTWM2OD1{Mj63N|EzKM7:TR?= MYrTRW5ITVJ?
MKN28 M{\vPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH1UFBJUUN3ME2yNk46ODF3IN88US=> M{W3enNCVkeHUh?=
ECC10 NYLkUIRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\2dmlEPTB;MkOuO|QyKM7:TR?= NHzLeFdUSU6JRWK=
BHT-101 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ2LkCwNFgh|ryP NES3XotUSU6JRWK=
DU-4475 M17nZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ2LkOzN|ch|ryP NVjvc4tuW0GQR1XS
769-P MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ2Lki0OlYh|ryP MknZV2FPT0WU
HEC-1 M{XNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjVZWlKSzVyPUK1MlQ1PSEQvF2= MV7TRW5ITVJ?
MOLT-13 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;GTWM2OD1{NT61N|MyKM7:TR?= NYG4TZEzW0GQR1XS
8505C NIjucpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nwNGlEPTB;Mk[uOFk4PyEQvF2= Mm\hV2FPT0WU
GB-1 NV;Mc2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\k[GRSUUN3ME2yOk44OTd4IN88US=> MoruV2FPT0WU
SF126 NYDETnhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq3VWlEUUN3ME2yOk44PjR6IN88US=> Mm[1V2FPT0WU
A4-Fuk NWXJ[XVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ5LkGyO|Eh|ryP NX30SHdqW0GQR1XS
OVCAR-8 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDwXJlKSzVyPUK3MlE2OzlizszN NEXJcFlUSU6JRWK=
NCI-H1304 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK4eZRKSzVyPUK3MlU1KM7:TR?= Ml\rV2FPT0WU
GR-ST M3vmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ6LkC0O{DPxE1? NVSwelk3W0GQR1XS
G-401 NGTZT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\ZTWM2OD1{OD61NFk3KM7:TR?= NYDycWVPW0GQR1XS
LXF-289 NE[4fZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;OVVdKSzVyPUK4MlU3PTFizszN NVrzR4hmW0GQR1XS
DBTRG-05MG M{LRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ6LkmyNFQh|ryP MnPNV2FPT0WU
YKG-1 M2fLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILXdFBKSzVyPUK5Mlg3QCEQvF2= NYfDSXo{W0GQR1XS
GAMG NF;UXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ7Lkm5N{DPxE1? MV;TRW5ITVJ?
HCT-116 M4PjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfDeZB2UUN3ME2zNE4xPTR6IN88US=> MXHTRW5ITVJ?
S-117 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj0NpNHUUN3ME2zNU4zOjV5IN88US=> NUPwPGNTW0GQR1XS
NCI-H1693 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj3TWM2OD1|Mz62OVQzKM7:TR?= M2LJ[nNCVkeHUh?=
A427 M4HuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ufotqUUN3ME2zN{46QTd4IN88US=> MmriV2FPT0WU
HT-29 NEK1dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\UTWM2OD1|ND62NFMzKM7:TR?= NWLCWnIzW0GQR1XS
P12-ICHIKAWA NFfMTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjSOFJ2UUN3ME2zOE44PDlzIN88US=> M2mzXHNCVkeHUh?=
CAL-51 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[4SlJDUUN3ME2zOU4xPzB7IN88US=> MkHWV2FPT0WU
Ramos-2G6-4C10 NX\qfpJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz1TWM2OD1|NT6yOFI2KM7:TR?= NYLKUIRXW0GQR1XS
SCH MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX6Uo1NUUN3ME2zOk41OTd2IN88US=> NHK0blBUSU6JRWK=
SK-MEL-24 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjITWM2OD1|Nj65NFQ1KM7:TR?= MW\TRW5ITVJ?
SW1573 NF\xSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTN6LkeyNVYh|ryP NF\HVlFUSU6JRWK=
BALL-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTN7LkKxNlkh|ryP NXHv[4xbW0GQR1XS
BE-13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HtVGlEPTB;M{muN|I6KM7:TR?= M{jKdnNCVkeHUh?=
GI-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTN7Lki2OFch|ryP MXTTRW5ITVJ?
GOTO M3TFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\kd5hHUUN3ME2zPU46OTN7IN88US=> NXu2TmFDW0GQR1XS
A673 NIHlT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\1TWM2OD12MT6wN|Q{KM7:TR?= NXXPWHU{W0GQR1XS
KG-1 M1zqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTR|LkO5OEDPxE1? NE\LeY9USU6JRWK=
GP5d NXTLcnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ETWlEPTB;NESuNFY3PiEQvF2= NV;LeZQ6W0GQR1XS
MFM-223 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG2TWM2OD12ND6xNlI5KM7:TR?= M2fOSnNCVkeHUh?=
OAW-42 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjlT5JuUUN3ME20OE4zPjR|IN88US=> MYHTRW5ITVJ?
C8166 NHvIWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDwco5KSzVyPUS1MlA5OjJizszN M4rFenNCVkeHUh?=
LU-99A NF20[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\zU5VKSzVyPUS2MlE{OjJizszN MlHHV2FPT0WU
NCI-H23 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[1bWVUUUN3ME20Ok4yPzh3IN88US=> MWjTRW5ITVJ?
HO-1-N-1 M2OxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL4TWM2OD12Nz6wPVk5KM7:TR?= NYHjVlFbW0GQR1XS
A3-KAW M1r0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m2fWlEPTB;NEeuNVAxPyEQvF2= MlvxV2FPT0WU
CGTH-W-1 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR5LkWwOlkh|ryP MmHuV2FPT0WU
DJM-1 NF73PGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTR5LkW0NVMh|ryP MVjTRW5ITVJ?
A101D M1;rSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr3O2FKSzVyPUS3MlY{PTdizszN NYfSe3Q3W0GQR1XS
BB30-HNC MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\LTWM2OD12OD6zNFczKM7:TR?= MVnTRW5ITVJ?
T98G Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;TfmlEPTB;NEiuOFY{OyEQvF2= M12wfXNCVkeHUh?=
NCI-H1573 NFH4O|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\FO455UUN3ME20PU41PDZ{IN88US=> NX;vb4dFW0GQR1XS
MEG-01 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPScJZKSzVyPUS5Mlc1OTFizszN MVLTRW5ITVJ?
WM-115 NFjBd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljCTWM2OD12OT65NlIzKM7:TR?= M1LMW3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
細胞試験:

[1]

+ 展開
  • 細胞株: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • 濃度: 1-300 nM
  • 反応時間: 7-14 days
  • 実験の流れ:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • 製剤: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • 投薬量: 50 mg/kg
  • 投与方法: Administered via i.p. injection at 10 μL/g of body weight
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 86 mg/mL (197.94 mM) warming
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 434.46
化学式

C24H23FN4O3

CAS No. 763113-22-0
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03561870 Not yet recruiting Recurrent IDH|Mutant High Grade Glioma Hospices Civils de Lyon December 1 2019 Phase 2
NCT03741426 Not yet recruiting Renal Cell Cancer CCTU- Cancer Theme|University of Cambridge|AstraZeneca|Cancer Research UK|Cambridge University Hospitals NHS Foundation Trust July 25 2019 Phase 2
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System March 1 2019 Phase 1
NCT03740893 Not yet recruiting Breast Neoplasm Institute of Cancer Research United Kingdom|AstraZeneca February 2019 Phase 2
NCT03742895 Not yet recruiting Advanced Solid Neoplasms Merck Sharp & Dohme Corp. December 17 2018 Phase 2
NCT03740165 Not yet recruiting Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms Merck Sharp & Dohme Corp.|European Network for Gynaecological Oncological Trial Groups December 14 2018 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • 回答:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • 質問2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • 回答:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • 質問3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • 回答:

    The compound is stable in DMEM at 4 degree for one week.

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品

Tags: Olaparib (AZD2281, Ku-0059436)を買う | Olaparib (AZD2281, Ku-0059436) ic50 | Olaparib (AZD2281, Ku-0059436)供給者 | Olaparib (AZD2281, Ku-0059436)を購入する | Olaparib (AZD2281, Ku-0059436)費用 | Olaparib (AZD2281, Ku-0059436)生産者 | オーダーOlaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)化学構造 | Olaparib (AZD2281, Ku-0059436)分子量 | Olaparib (AZD2281, Ku-0059436)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID